Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Product sales	$ 11,021,821	$ 8,226,992
Cost of product sales	4,275,348	3,448,294
Gross profit	6,746,473	4,778,698
Operating expenses
Research and development	1,193,415	2,028,465
Sales and marketing	2,086,426	3,009,537
General and administrative	4,522,479	4,592,235
Total operating expenses	7,802,320	9,630,237
Operating loss	(1,055,847)	(4,851,539)
Other income (expenses)
Interest income	350	2,420
Interest expense	(190,069)	(100,000)
Loss on deconsolidation of biologistex	0	(2,785,910)
Loss from equity-method investment in SAVSU	(1,004,880)	0
Financing costs and write off of deferred financing costs	(108,664)	(86,736)
Amortization of debt discount	(155,996)	(218,394)
Loss on disposal of property and equipment	0	(1,213)
Total other income (expenses)	(1,459,259)	(3,189,833)
Net Loss	(2,515,106)	(8,041,372)
Net Loss attributable to non-controlling interest	0	1,165,926
Net Loss attributable to BioLife Solutions, Inc.	(2,515,106)	(6,875,446)
Less: Preferred stock dividends	(212,500)	0
Net loss attributable to common stockholders	$ (2,727,606)	$ (6,875,446)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc.	$ (0.21)	$ (0.54)
Basic and diluted weighted average common shares used to calculate net loss per common share	13,263,881	12,642,996